Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 7/20 | 0.48 |
| ▸ | CTSB | P07858 | 2/20 | 0.47 |
| ▸ | DPP4 | P27487 | 3/20 | 0.45 |
| ▸ | FAP | Q12884 | 1/20 | 0.45 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.45 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.45 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.45 |
| ▸ | PLG | P00747 | 2/20 | 0.40 |
| ▸ | PLAT | P00750 | 2/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2194423 | 1.00 | CAPN1 (0.48) | CAPN1CTSBDPP4FAPDPP8 | |
| SCHEMBL21519838 | 1.00 | CAPN1 (0.48) | CAPN1CTSBDPP4FAPDPP8 | |
| SCHEMBL29616517 | 0.98 | CAPN1 (0.51) | CAPN1CTSBDPP4FAPDPP8 | |
| SCHEMBL30800860 | 0.90 | DPP4 (0.44) | CAPN1CTSBDPP4FAPDPP8 | |
| SCHEMBL29397117 | 0.89 | DPP4 (0.46) | CAPN1CTSBDPP4FAPDPP8 | |
| SCHEMBL30800861 | 0.89 | DPP4 (0.43) | CAPN1CTSBDPP4FAPDPP8 | |
| SCHEMBL29397226 | 0.87 | DPP4 (0.44) | CAPN1CTSBDPP4FAPDPP8 | |
| SCHEMBL15481300 | 0.87 | DPP4 (0.42) | CAPN1CTSBDPP4FAPDPP8 | |
| SCHEMBL30800866 | 0.84 | DPP4 (0.40) | CAPN1CTSBDPP4FAPDPP8 | |
| SCHEMBL29765255 | 0.84 | CAPN1 (0.47) | CAPN1CTSBDPP4FAPDPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250339372-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A GLP-1-AGONIST AND METHIONINE | SANOFI AVENTIS DEUTSCHLAND (DE) | 2025-11-06 | — | — | US | disclosed |
| US-20250206798-A1 | INSULIN CONJUGATES | SANOFI SA (FR) | 2025-06-26 | — | — | US | disclosed |
| US-12303598-B2 | Pharmaceutical composition comprising a GLP-1-agonist and methionine | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2025-05-20 | — | — | US | disclosed |
| US-20250032721-A1 | Supplemental Device for Attachment to an Injection Device | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2025-01-30 | — | — | US | disclosed |
| US-20240390500-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A GLP-1 AGONIST, AN INSULIN AND METHIONINE | SANOFI AVENTIS DEUTSCHLAND (DE) | 2024-11-28 | — | — | US | disclosed |
| US-20240174728-A1 | A USE OF A POLYPEPTIDE COMPOUND IN THE PREPARATION OF DRUGS FOR PREVENTING OR TREATING INFLAMMATORY BOWEL DISEASES AND RELATED INTESTINAL FIBROSIS | SHENZHEN TURIER BIOTECH CO., LTD. (CN) | 2024-05-30 | — | — | US | disclosed |
| US-11654183-B2 | Methods comprising continuous administration of exenatide and co-administration of a drug | INTARCIA THERAPEUTICS, INC. (US) | 2023-05-23 | — | — | US | disclosed |
| US-20230028647-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A GLP-1-AGONIST AND METHIONINE | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2023-01-26 | — | — | US | disclosed |
| US-20220265776-A1 | COMBINATION | GENESIS PHARMA SA (GR) | 2022-08-25 | — | — | US | disclosed |
| US-11419986-B2 | Supplemental device for attachment to an injection device | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2022-08-23 | — | — | US | disclosed |
| EP-3996717-A1 | COMBINATION | Genesis Pharma SA (GR) | 2022-05-18 | — | — | EP | disclosed |
| US-20220133890-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A GLP-1 AGONIST, AN INSULIN AND METHIONINE | SANOFI AVENTIS DEUTSCHLAND (DE) | 2022-05-05 | — | — | US | disclosed |
| US-20190328887-A1 | METABOLICALLY STABLE PEPTIDE ANALOGS | UNIVERSITÉ DE STRASBOURG (FR) | 2019-10-31 | — | — | US | disclosed |
| US-8680263-B2 | Carbohydrate-based drug delivery polymers and conjugates thereof | NEKTAR THERAPEUTICS (US) | 2014-03-25 | — | — | US | disclosed |
| US-20120129817-A1 | COMBINATION TREATMENT FOR DIABETES MELLITUS | NYCOMED GMBH (DE) | 2012-05-24 | — | — | US | disclosed |
| US-20110171716-A1 | CARBOHYDRATE-BASED DRUG DELIVERY POLYMERS AND CONJUGATES THEREOF | NEKTAR THERAPEUTICS (US) | 2011-07-14 | — | — | US | disclosed |
| US-20110166063-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NEKTAR THERAPEUTICS (US) | 2011-07-07 | — | — | US | disclosed |
| US-20100179131-A1 | Combination treatment for diabetes mellitus | NYCOMED GMBH (DE) | 2010-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129817-A1 | COMBINATION TREATMENT FOR DIABETES MELLITUS | GPR119, IAPP, MTNR1B | CAPN1 2683/4885CTSB 2900/4885DPP4 7/4885 |
| US-20110171716-A1 | CARBOHYDRATE-BASED DRUG DELIVERY POLYMERS AND CONJUGATES THEREOF | STT3B, STT3A, DDOST | CAPN1 2227/4885CTSB 1801/4885DPP4 193/4885 |
| US-20190328887-A1 | METABOLICALLY STABLE PEPTIDE ANALOGS | GPR119, GLP1R, GRPR | CAPN1 4671/4885CTSB 1685/4885DPP4 342/4885 |
| US-20240174728-A1 | A USE OF A POLYPEPTIDE COMPOUND IN THE PREPARATION OF DRUGS FOR PREVENTING OR TREATING INFLAMMATORY BOWEL DISEASES AND RELATED INTESTINAL FIBROSIS | VIP, FN1, COL14A1 | CAPN1 3648/4885CTSB 1040/4885DPP4 1561/4885 |
| US-20110166063-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NGLY1, CD44, IAPP | CAPN1 2889/4885CTSB 1261/4885DPP4 525/4885 |
| US-20250206798-A1 | INSULIN CONJUGATES | IAPP, INSR, IGF1R | CAPN1 4301/4885CTSB 2977/4885DPP4 714/4885 |
| US-20100179131-A1 | Combination treatment for diabetes mellitus | GPR119, GLP1R, MTNR1B | CAPN1 3730/4885CTSB 2648/4885DPP4 5/4885 |
| US-20220265776-A1 | COMBINATION | GLP1R, IAPP, GCG | CAPN1 3539/4885CTSB 2305/4885DPP4 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.